Insight

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

Collage photo of Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer

Nov 10, 2024, 16:37

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

A recent paper by Guilherme Nader-Marta, Clinical Fellow at Dana-Farber Cancer Institute, was mentioned by Dana-Farber’s Breast Oncology Center on X:

“Check out this new editorial in ESMO Open on the incorporation of immunotherapy in the management of early-stage estrogen receptor-positive Breast Cancer.”

“Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer”

Authors: Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer.

Posts featuring Dana-Farber’s Breast Oncology Center

Adrienne Waks cancer Dana-Farber’s Breast Oncology Center ER+ breast cancer Erica Mayer ESMO Open Guilherme Nader Marta OncoDaily Oncology Sara Tolaney

10 Leading Experts Join OncoDaily Journal Editorial Team

Top 10 Oncogrants of the Week: Fueling Cancer Research and Innovation

Soon-Shiong’s “Bioshield” Sparks Early Promise in Recurrent GBM, With 2 Near-CRs and 100% Disease Control

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer